Safety and Efficacy of J147 in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.
Also called NCT07430917
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 196 participants
- Sponsor
- Abrexa Pharmaceuticals, Inc.
- Registry
-
NCT07430917
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07430917. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-22 (actual); primary completion 2028-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of J147 in Acute Ischemic Stroke
- Acronym
- JUMPSTART
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- J147 Emulsion for Injection
- Intervention (Other)
- Placebo
- Lead sponsor
- Abrexa Pharmaceuticals, Inc.
- Collaborator
- IQVIA RDS Inc.
Record details
- Record id
cardio:ct-nct07430917- Content hash
ad2e7903374e1e8f752c86d8bef7a2ac5bb83760b17318220c076d69ea5ea769